Detalles de la búsqueda
1.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet
; 399(10324): 541-553, 2022 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123694
2.
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Gynecol Oncol
; 167(3): 429-435, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36244828
3.
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
Gynecol Oncol
; 155(3): 393-399, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31653510
4.
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Gynecol Oncol
; 146(2): 247-253, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28532857
5.
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 141(1): 43-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27016228
6.
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 143(3): 511-515, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27692669
7.
Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
Int J Gynecol Cancer
; 26(5): 971-6, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27101581
8.
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol
; 135(1): 44-8, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25091619
9.
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.
Gynecol Oncol
; 133(3): 537-41, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24594074
10.
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Gynecol Oncol
; 132(3): 585-92, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24456823
11.
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
J Clin Oncol
; : JCO2301279, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38662968
12.
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Gynecol Oncol
; 129(3): 486-94, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23438670
13.
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Gynecol Oncol
; 127(2): 345-50, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22885469
14.
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
Gynecol Oncol
; 127(2): 356-61, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22796461
15.
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
Gynecol Oncol
; 120(3): 459-63, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21144560
16.
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecol Oncol
; 121(3): 455-61, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21414654
17.
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
Gynecol Oncol
; 122(1): 89-94, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21529904
18.
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
J Natl Cancer Inst
; 113(10): 1369-1378, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33729494
19.
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
J Clin Oncol
; 38(33): 3841-3850, 2020 11 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33078978
20.
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
Gynecol Oncol
; 113(3): 341-7, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19272639